Posts Tagged: healthcare technologies

Five UTEST companies to tackle critical healthcare challenges

Program's second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD TORONTO (May 14, 2013) — Five companies tackling pervasive healthcare challenges — such as assessing dental health, helping patients and medical personnel navigate hospitals with greater ease, staying current with medical literature, or creating digital tools to help care for the elderly or those with chronic health conditions — have been admitted to the University of Toronto Early Stage Technology (UTEST) program’s second cohort. UTEST, supported by the University of ... Read more

How Canada’s health-care industry is riding a wave of transition

Bedside Clinical Systems featured on Research Innovation and Commercialization Centre (RICC) panel discussion In an article for YourMississaugaBiz.com, Jon Cook writes, " 'The health-care industry is relying more on the private sector for innovation and small businesses need to make sure they have a strong value proposition in order to get their projects funded,' said Telus Health executive Nicholas Zamora." The article describes a panel discussion organized by the Research Innovation and Commercialization Centre (RICC) on the "intersection of health care and technology ... Read more

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. “There’s growing consensus that transferring technologies from the university lab ... Read more

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector. Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ... Read more

Xconomy names Xagenic to 2012’s Biotech Startup Class

MI spin-off company one of 30 listed in North America and the United Kingdom Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class. Luke Timmerman's article, published December 3, 2012, sited Xagenic as one of only 30 "exciting biotech startups" to raise significant venture capital (at least $5 million) in the life sciences sector. Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto,  was also the only Canadian company named to the list. (more…) Read more

Baxter and MaRS Innovation Form Strategic Partnership

Partnership to invest up to $1M in promising Canadian healthcare discoveries TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies. Information about Baxter and MaRS Innovation's partnership is also available in French. The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will ... Read more

DLVR Therapeutics Inc. adds MaRS Innovation to investor base

TORONTO, Ontario, Canada – October 24, 2011 – DLVR Therapeutics Inc. (“DLVR”) - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle - announced today that the company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support. MaRS Innovation joins the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in the company. The additional funds will be ... Read more

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it - part of a growing trend of selling science to help shore up Canada's troubled health-care system. Tuesday's agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question. But the licensing deal with one of the world's biggest drug companies ... Read more

How VitalHub Corp. Uses iPhones® To Help Health Care

TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp.. The unique start-up company was spun-off from mobile health technologies developed  Toronto's Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector. MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto's ... Read more

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread. Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 ... Read more
Page 3 of 41234